» Articles » PMID: 39200936

Metamizole in the Management of Musculoskeletal Disorders: Current Concept Review

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Aug 29
PMID 39200936
Authors
Affiliations
Soon will be listed here.
Abstract

Metamizole, or dipyrone, has been used for decades as a non-narcotic analgesic, providing pain relief from musculoskeletal disorders and antipyretic and antispasmolytic properties. Despite being in use since the 1920s, its mechanism of action still needs to be discovered. Despite causing fewer adverse effects when compared to other analgesics, its harmful effects on the blood and lack of evidence regarding its teratogenicity make the usage of the drug questionable, which has led to it being removed from the drug market of various countries. This narrative review aims to provide a detailed insight into the mechanism of action and efficacy, comparing its effectiveness and safety with other classes of drugs and the safety profile of metamizole.

References
1.
Zhang J, Ding E, Song Y . Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006; 296(13):1619-32. DOI: 10.1001/jama.296.13.jrv60015. View

2.
Stessel B, Boon M, Pelckmans C, Joosten E, Ory J, Wyckmans W . Metamizole vs. ibuprofen at home after day case surgery: A double-blind randomised controlled noninferiority trial. Eur J Anaesthesiol. 2019; 36(5):351-359. DOI: 10.1097/EJA.0000000000000972. View

3.
Sener M, Yilmazer C, Yilmaz I, Bozdogan N, Ozer C, Donmez A . Efficacy of lornoxicam for acute postoperative pain relief after septoplasty: a comparison with diclofenac, ketoprofen, and dipyrone. J Clin Anesth. 2008; 20(2):103-8. DOI: 10.1016/j.jclinane.2007.09.009. View

4.
Jasiecka A, Maslanka T, Jaroszewski J . Pharmacological characteristics of metamizole. Pol J Vet Sci. 2014; 17(1):207-14. DOI: 10.2478/pjvs-2014-0030. View

5.
. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023; 5(6):e316-e329. PMC: 10234592. DOI: 10.1016/S2665-9913(23)00098-X. View